BMS' Eliquis: NICE fast-track yes for VTE but its no better than Xarelto or Pradaxa
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has today published final guidance recommending Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) as an option for preventing venous thromboembolism after knee and hip surgery.